Specialty Diagnostics — Research and development expenses
Business Segments · Research and development expensesThermo Fisher Scientific Specialty Diagnostics — Research and development expenses decreased by 4.5% to $42.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.5%, from $44.00M to $42.00M.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2023
Last reportedQ3 2025
Rolls up toR&D
How to read this metric
Increased investment suggests a focus on long-term innovation, while decreased investment may signal a shift toward cost-cutting or a mature product cycle.
Detailed definition
Expenditures dedicated to the discovery, development, and improvement of new diagnostic technologies, reagents, and clin...
Peer comparison
Critical metric for evaluating competitive positioning in the highly innovative diagnostic market.
Metric ID:
tmo_segment_specialty_diagnostics_research_and_development_expensesHistorical Data
6 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $39.00M | $39.00M | $39.00M | $39.00M | $44.00M | $42.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +12.8% | -4.5% |
| YoY Change | — | — | — | — | +12.8% | -4.5% |
Range$39.00M – $44.00M
CAGR+6.1%
Avg YoY Growth+4.1%
Median YoY Growth+4.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's specialty diagnostics — research and development expenses?
- Thermo Fisher Scientific (TMO) reported specialty diagnostics — research and development expenses of $42.00M in Q3 2025.
- How has Thermo Fisher Scientific's specialty diagnostics — research and development expenses changed year-over-year?
- Thermo Fisher Scientific's specialty diagnostics — research and development expenses decreased by 4.5% year-over-year, from $44.00M to $42.00M.
- What does specialty diagnostics — research and development expenses mean?
- Money spent on developing new products and improving existing ones in the Specialty Diagnostics segment.